0000000000166734
AUTHOR
Russo M
Le dimensioni affettive nella comunicazione della "cattiva notizia"
Vite di cristallo: l'identità psicocorporea in soggetti emofilici
Comunicare "cattive notizie" in oncologia
Cura psicologica in emergenza: un caso clinico
Il linguaggio tecnicistico e la comunicazione per la salute
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia
Eltrombopag is an oral thrombopoietin-receptor agonist. This study evaluated the efficacy of eltrombopag for increasing platelet counts and reducing the need for platelet transfusions in patients with thrombocytopenia and chronic liver disease who are undergoing an elective invasive procedure.We randomly assigned 292 patients with chronic liver disease of diverse causes and platelet counts of less than 50,000 per cubic millimeter to receive eltrombopag, at a dose of 75 mg daily, or placebo for 14 days before a planned elective invasive procedure that was performed within 5 days after the last dose. The primary end point was the avoidance of a platelet transfusion before, during, and up to 7…